Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development

Jessica Gillen, Debra L Richardson, Kathleen Moore

Research output: Contribution to journalReview article

Abstract

Purpose of Review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition. Recent Findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. Summary: The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.

Original languageEnglish (US)
Article number22
JournalCurrent Oncology Reports
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2019
Externally publishedYes

Fingerprint

Angiopoietins
Angiopoietin-2
Angiopoietin-1
Clinical Trials
Tumor Burden
Renal Cell Carcinoma
Neoplasms
Breast
Neoplasm Metastasis
Therapeutics
Growth

Keywords

  • Angiogenesis
  • Angiopoietin inhibition
  • Anti-angiogenic therapy
  • Tie2 inhibition

ASJC Scopus subject areas

  • Oncology

Cite this

Angiopoietin-1 and Angiopoietin-2 Inhibitors : Clinical Development. / Gillen, Jessica; Richardson, Debra L; Moore, Kathleen.

In: Current Oncology Reports, Vol. 21, No. 3, 22, 01.03.2019.

Research output: Contribution to journalReview article

@article{2dfd165dbd0a4f6390c61d45250d508d,
title = "Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development",
abstract = "Purpose of Review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition. Recent Findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. Summary: The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.",
keywords = "Angiogenesis, Angiopoietin inhibition, Anti-angiogenic therapy, Tie2 inhibition",
author = "Jessica Gillen and Richardson, {Debra L} and Kathleen Moore",
year = "2019",
month = "3",
day = "1",
doi = "10.1007/s11912-019-0771-9",
language = "English (US)",
volume = "21",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Angiopoietin-1 and Angiopoietin-2 Inhibitors

T2 - Clinical Development

AU - Gillen, Jessica

AU - Richardson, Debra L

AU - Moore, Kathleen

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Purpose of Review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition. Recent Findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. Summary: The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.

AB - Purpose of Review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition. Recent Findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. Summary: The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.

KW - Angiogenesis

KW - Angiopoietin inhibition

KW - Anti-angiogenic therapy

KW - Tie2 inhibition

UR - http://www.scopus.com/inward/record.url?scp=85062145462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062145462&partnerID=8YFLogxK

U2 - 10.1007/s11912-019-0771-9

DO - 10.1007/s11912-019-0771-9

M3 - Review article

C2 - 30806847

AN - SCOPUS:85062145462

VL - 21

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 3

M1 - 22

ER -